Neurocrine Biosciences Inc (NBIX)
Solvency ratios
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt-to-assets ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.07 | 0.00 | 0.00 | 0.08 | 0.18 | 0.16 | 0.16 | 0.17 | 0.17 | 0.18 | 0.28 | 0.28 | 0.30 |
| Debt-to-capital ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.09 | 0.00 | 0.00 | 0.11 | 0.21 | 0.20 | 0.20 | 0.20 | 0.21 | 0.22 | 0.35 | 0.34 | 0.37 |
| Debt-to-equity ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.10 | 0.00 | 0.00 | 0.12 | 0.27 | 0.24 | 0.25 | 0.26 | 0.27 | 0.28 | 0.53 | 0.50 | 0.59 |
| Financial leverage ratio | 1.44 | 1.30 | 1.32 | 1.46 | 1.46 | 1.42 | 1.41 | 1.40 | 1.39 | 1.39 | 1.41 | 1.54 | 1.51 | 1.50 | 1.53 | 1.53 | 1.54 | 1.87 | 1.82 | 1.94 |
The solvency ratios of Neurocrine Biosciences Inc show a strong and improving financial position over the years.
- The debt-to-assets ratio has declined steadily from 0.30 in March 2020 to 0.00 by September 2024, indicating a decreasing reliance on debt to finance its assets.
- The debt-to-capital ratio followed a similar trend, decreasing from 0.37 in March 2020 to 0.00 by September 2024, reflecting a decreasing proportion of debt in the company's capital structure.
- The debt-to-equity ratio also exhibited a declining pattern, decreasing from 0.59 in March 2020 to 0.00 by September 2024, indicating a decreasing dependence on debt relative to equity.
- The financial leverage ratio, which combines debt and equity to measure financial risk, has shown a decreasing trend over the years, from 1.94 in March 2020 to 1.44 by December 2024. This reduction signifies a lower level of financial risk and a stronger balance sheet.
Overall, the solvency ratios of Neurocrine Biosciences Inc suggest a prudent approach to managing debt and a strengthening financial position, which bodes well for the company's long-term stability and sustainability.
Coverage ratios
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Interest coverage | 4.00 | 4.42 | 3.86 | 103.15 | 73.20 | 55.74 | 50.81 | 16.93 | 31.13 | 7.52 | 1.82 | 5.35 | 4.93 | 6.81 | 3.40 | 4.06 | 4.25 | 4.12 | 7.70 | 6.82 |
The interest coverage ratio measures a company's ability to cover its interest expenses with its operating income. A higher ratio indicates that the company is in a better position to meet its interest obligations.
Analyzing the interest coverage ratio of Neurocrine Biosciences Inc over the past few quarters, we observe fluctuations in the ratio. The ratio ranged from a low of 1.82 in June 30, 2022, to a high of 103.15 in March 31, 2024. The significant increase in the ratio in March 31, 2024, may be an anomaly or the result of a one-time event.
Overall, the trend in the interest coverage ratio shows some inconsistency, with fluctuations indicating potential variability in the company's ability to cover its interest expenses. It would be important to further investigate the reasons behind these fluctuations to assess the company's long-term financial stability and ability to meet its debt obligations.